Warning: The NCBI web site requires JavaScript to function. more...
Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A.
Malar J. 2007 Aug 8;6:107.
Related citations
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP.
PLoS One. 2008 Jul 9;3(7):e2636.
Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
Arakawa T, Komesu A, Otsuki H, Sattabongkot J, Udomsangpetch R, Matsumoto Y, Tsuji N, Wu Y, Torii M, Tsuboi T.
Infect Immun. 2005 Nov;73(11):7375-80.
Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
Kongkasuriyachai D, Bartels-Andrews L, Stowers A, Collins WE, Sullivan J, Sattabongkot J, Torii M, Tsuboi T, Kumar N.
Vaccine. 2004 Aug 13;22(23-24):3205-13.
Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.
Coban C, Philipp MT, Purcell JE, Keister DB, Okulate M, Martin DS, Kumar N.
Infect Immun. 2004 Jan;72(1):253-9.
Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
Mlambo G, Maciel J, Kumar N.
Infect Immun. 2008 May;76(5):2018-24. Epub 2008 Mar 3.
Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
Blagborough AM, Yoshida S, Sattabongkot J, Tsuboi T, Sinden RE.
Vaccine. 2010 Aug 23;28(37):6014-20. Epub 2010 Jul 14.
Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes.
Arakawa T, Tsuboi T, Kishimoto A, Sattabongkot J, Suwanabun N, Rungruang T, Matsumoto Y, Tsuji N, Hisaeda H, Stowers A, Shimabukuro I, Sato Y, Torii M.
Vaccine. 2003 Jul 4;21(23):3143-8.
Efficacy model for mosquito stage transmission blocking vaccines for malaria.
Saul A.
Parasitology. 2008 Nov;135(13):1497-506. Epub 2008 Feb 7.
The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
Ramjanee S, Robertson JS, Franke-Fayard B, Sinha R, Waters AP, Janse CJ, Wu Y, Blagborough AM, Saul A, Sinden RE.
Vaccine. 2007 Jan 15;25(5):886-94. Epub 2006 Sep 20.
Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism.
Hisaeda H, Collins WE, Saul A, Stowers AW.
Vaccine. 2001 Dec 12;20(5-6):763-70.
Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
Miyata T, Harakuni T, Sugawa H, Sattabongkot J, Kato A, Tachibana M, Torii M, Tsuboi T, Arakawa T.
Vaccine. 2011 Mar 24;29(15):2720-6. Epub 2011 Feb 11.
A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies.
Stowers AW, Keister DB, Muratova O, Kaslow DC.
Infect Immun. 2000 Oct;68(10):5530-8.
Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.
Arévalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincón A, Saul A, Mu J, Long C, Miller L, Herrera S.
Am J Trop Med Hyg. 2005 Nov;73(5 Suppl):32-7.
Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
Sattabongkot J, Tsuboi T, Hisaeda H, Tachibana M, Suwanabun N, Rungruang T, Cao YM, Stowers AW, Sirichaisinthop J, Coleman RE, Torii M.
Am J Trop Med Hyg. 2003 Nov;69(5):536-41.
Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity.
Farrance CE, Chichester JA, Musiychuk K, Shamloul M, Rhee A, Manceva SD, Jones RM, Mamedov T, Sharma S, Mett V, Streatfield SJ, Roeffen W, van de Vegte-Bolmer M, Sauerwein RW, Wu Y, Muratova O, Miller L, Duffy P, Sinden R, Yusibov V.
Hum Vaccin. 2011 Jan-Feb;7 Suppl:191-8. Epub 2011 Jan 1.
Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen.
Mlambo G, Kumar N, Yoshida S.
Vaccine. 2010 Oct 8;28(43):7025-9. Epub 2010 Aug 13.
Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.
Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC.
Infect Immun. 2000 Dec;68(12):6618-23.
Transmission-blocking vaccine of vivax malaria.
Tsuboi T, Tachibana M, Kaneko O, Torii M.
Parasitol Int. 2003 Mar;52(1):1-11. Review.
Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.
Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, Shiloach J, Robbins JB, Schneerson R.
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):293-8. Epub 2006 Dec 26.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on